{
  "docId": "019dd923-5efe-75c0-8dfe-c33214992e60",
  "docSlug": "e4e961afe28a39dc",
  "documentTitle": "2026 Investor Deck",
  "authorId": "JPMorgan-IR",
  "authorName": "Summit Therapeutics",
  "documentKindSlug": "consulting-deck",
  "documentKindLabel": "Consulting deck",
  "sourceTypeSlug": "strategy_consulting",
  "sourceTypeLabel": "Strategy consulting",
  "presentationDate": null,
  "orientation": "landscape",
  "aspectRatio": 1.778,
  "pageNumber": 5,
  "pageCount": 15,
  "prevPage": 4,
  "nextPage": 6,
  "slideType": "other",
  "function": "present_solution",
  "density": "dense",
  "nDataPoints": 0,
  "notes": "The slide uses a scientific illustration to explain the molecular mechanism of a bispecific antibody.",
  "elementsJson": [
    "headline_text",
    "action_title",
    "photo",
    "bullet_list",
    "footnote"
  ],
  "metadataConfidence": 0.95,
  "imagePath": null,
  "slideHref": "/slides/019dd923-5efe-75c0-8dfe-c33214992e60/5",
  "deckHref": "/decks/019dd923-5efe-75c0-8dfe-c33214992e60",
  "deckJsonHref": "/decks/019dd923-5efe-75c0-8dfe-c33214992e60.json",
  "deckAnchorHref": "/decks/019dd923-5efe-75c0-8dfe-c33214992e60#slide-5",
  "components": [
    {
      "bbox": null,
      "kind": "callout",
      "text": "Presence of VEGF-A efficiently enhances the binding affinity to PD-1 by several fold (in vitro).",
      "attrs": null,
      "subkind": null,
      "toolName": "Visual emphasis",
      "toolSlug": "visual-emphasis",
      "confidence": null,
      "componentId": "019dd952-8f70-769d-bf2f-25ccc45cac29",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.5,
        "w": 0.28,
        "x": 0.08,
        "y": 0.225
      },
      "kind": "image",
      "text": "Scientific diagram showing ivonescimab binding to PD-1 and VEGF in the tumor microenvironment",
      "attrs": null,
      "subkind": "illustration",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2f6953bd-6860-40bc-9697-3a921e9528c3",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.5,
        "x": 0.45,
        "y": 0.65
      },
      "kind": "list",
      "text": "Intentional, Potentially Favorable Molecular Profile: Structure may lead to optimized binding in TME; Targeting PD-1 may lead to better efficacy profile; 7 to 10-day half-life could potentially lead to a favorable safety profile.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4014a84f-5e2e-40e4-87c4-193e5bc49f57",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.5,
        "x": 0.45,
        "y": 0.35
      },
      "kind": "list",
      "text": "Enhanced Activity of T Cells: VEGF dimer leads to potential interconnection of ivonescimab molecules which may increase activity of T cells (in vitro)",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7b4a4e32-fcc1-4d52-8bad-eed8682cd27b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.5,
        "x": 0.45,
        "y": 0.08
      },
      "kind": "list",
      "text": "Increased Avidity in TME: Presence of VEGF-A efficiently enhances the binding affinity to PD-1 by several fold (in vitro)",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9c2739c8-6b54-4048-b3c9-c40ffc5d59f4",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.45,
        "x": 0.5,
        "y": 0.95
      },
      "kind": "source-note",
      "text": "Abbreviations: PD-1=programmed cell death protein 1; TME=tumor microenvironment; VEGF=vascular endothelial growth factor.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8c3f1669-d7b9-4cd0-b5e5-15496ae0b778",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.4,
        "x": 0.05,
        "y": 0.05
      },
      "kind": "title",
      "text": "Cooperative Binding Potentially Drives Synergistic Anti-Tumor Activity",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1e04e3d3-f54c-41e8-ac57-cde342bb6419",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Metaphor & Analogy",
      "slug": "metaphor-analogy",
      "agent": "Storyteller",
      "layer": "slide",
      "matchId": "c74bfd64-6760-4050-9bac-8cf04b366dea",
      "evidence": "Cooperative Binding Potentially Drives Synergistic Anti-Tumor Activity",
      "confidence": 0.6
    }
  ],
  "frameworks": [],
  "arcBeats": [],
  "loops": [
    {
      "to": 15,
      "from": 3,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "79e0c4c9-6f51-444c-a54b-594ca0500180",
      "evidence": "The deck implies the cost of inaction through its emphasis on Ivonescimab's development progress and potential",
      "position": 0,
      "objective": "Highlighting the importance of timely progress in biopharma development",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.6,
      "description": "Quantify what happens if the audience does nothing"
    },
    {
      "to": 11,
      "from": 4,
      "name": "Quick Win Big Bet",
      "slug": "47-quick-win-big-bet",
      "bestFor": "Transformation planning, 100-day plans, resource allocation",
      "matchId": "8d8d3398-4ad3-42b9-8a45-5223f61f6fa3",
      "evidence": "Slides 4-11 focus on Ivonescimab's clinical achievements and potential",
      "position": 1,
      "objective": "Positioning Ivonescimab as a high-potential therapy",
      "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap",
      "confidence": 0.7,
      "description": "Separate initiatives into immediate wins and longer-term strategic bets"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}